- ORGANIZED BY
- IN COOPERATION WITH
- SPONSOR
- SUPPORTERS
- MEDIA SPONSORS
- COMMUNICATION CONSULTANT
- CONFERENCE EXPERIENCE SPONSOR
Tuesday, January 26, 2021
According to the Minister of Health we are moving forward to the post-crisis era with a New National Pharmaceutical Policy that will ensure patients' access to affordable and reliable medicines as well as to pharmaceutical innovation. The broader vision incudes the universal and equal coverage of the health needs of the population from a patient centric, transparent, effective and financially viable public health system that will provide reliable care without unbearable financial burden on citizens.
The major question that we will attempt to approach in a Special Roundtable Discussion composed by Health Authorities, Payers, Industry, Patients, Health Economists is whether there is room for sustainable financing and effecient operation of the Health System in an environment under austerity and fiscal consolidation?
Beyond any doubt, under such a strict condition of compulsory austerity the State we must keep working and forward the necessary structural reforms, the strengthening of the capacity of the NHS and the gradual convergence of public health expenditure as a percentage of GDP with European averages. High on the Agenda is also the systematic promotion of the transnational cooperation for joint negotiations of affordable prices for high-cost medicines (the recently signed Valleta Declaration is the first step), the need for a consistent and fairer volume rebate, a better and more fair distribution of the public pharmaceutical expenditure’s over-spending, the modification of the Price List architecture to remove current distortions and of course a new way of calculating the insurance price to reduce the patient's financial burden.
In Greece, we are faced with a disproportional analogy of health needs and resources. This can only be addressed through a serious political plan that includes the necessary progressive reforms in the field of health, the more efficient organization and management of public structures, the upgrading of e-Government, scientific control of demand for medicines, tests and services and the increase of the capacity of the NHS and the quality of its services.